✉ Email this page to a colleague
« Back to Dashboard
BYL719 is an investigational drug.
There have been 59 clinical trials for BYL719. The most recent clinical trial was a Phase 2 trial, which was initiated on July 16th 2020.
The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Carcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).
There are two hundred and sixty-nine US patents protecting this investigational drug and three international patents.
Recent Clinical Trials for BYL719
|SMMART Adaptive Clinical Treatment (ACT) Trial||Genentech, Inc.||Phase 2|
|SMMART Adaptive Clinical Treatment (ACT) Trial||Oregon Health and Science University||Phase 2|
|SMMART Adaptive Clinical Treatment (ACT) Trial||OHSU Knight Cancer Institute||Phase 2|
Top disease conditions for BYL719
Top clinical trial sponsors for BYL719
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|BYL719||See Plans and Pricing||Substituted thiohydantoin derivatives as androgen receptor antagonists||Janssen Pharmaceutica NV (Beerse, BE)||See Plans and Pricing|
|BYL719||See Plans and Pricing||Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity||The University of North Carolina at Chapel Hill (Chapel Hill, NC)||See Plans and Pricing|
|BYL719||See Plans and Pricing||Compounds and compositions as inhibitors of MEK||Novartis AG (Basel, CH)||See Plans and Pricing|
|BYL719||See Plans and Pricing||Benzimidazole derivatives as bromodomain inhibitors||Gilead Sciences, Inc. (Foster City, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|BYL719||Argentina||AR107432||2036-01-11||See Plans and Pricing|
|BYL719||Australia||AU2017207268||2036-01-11||See Plans and Pricing|
|BYL719||Australia||AU2019203280||2036-01-11||See Plans and Pricing|
|BYL719||Australia||AU2021201018||2036-01-11||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|